ABSTRACT
INTRODUCTION
Over the recent years, as an understanding of radiation chemistry has developed, it has been possible to develop compounds which modify the initial radiochemical event. The recognition by Gray et al (1) in 1953 that oxygen had a major effect on radiosensitivity has led to extensive investigations into the potential for this factor in tumour therapy. Membranes and DNA are critical targets for ionizing radiation and may be major sites for the development of the oxygen effects (2) . Explanations of this effect have previously emphasised the involvement of reactive oxygen species such as the superoxide anion and the hydroxyl radical to explain some of the cytotoxic effects of ionizing radiations (3) . Free radicals are highly reactive molecular species. They react with almost every type of cellular molecules, causing metabolic disturbance, cell injury and even cell death (4) . Oxygen radicals are involved in tumour promotion and causative agents of the deleterious effects of ionizing radiation (5) .
Radiotherapy and chemotherapy are traditional cancer treatments, that increases DNA damage in tumour cells. Due to higher replication rate of tumour cells DNA repair mechanisms counteract the effects of radiation and chemotherapy treatment by promoting the replication of the tumour cells. It may be possible to prevent this process by inhibiting the DNA repair mechanism by radioprotective compounds.
Radiation damage to the heamatopoietic system is considered as the most commonly encountered disorders in radiation sickness. Reduction in the number of blood cells and damage to the bone marrow with resulting anaemia and haemorrhage have been profoundly observed (6) . Ionizing radiation, through production of oxygen radical species, can result in DNA damage, especially by forming thymidine hydroperoxyde (7) .
It has been suggested that various chemical structures may protect against the acute cell and tissue toxicities and delayed carcinogenesis that are induced by radiation via generation of free radicals and various ionic species (8)
RADIOPROTECTIVE AGENTS IN MEDICINE
Current multidisciplinary research in the field of radioprotection involves all aspects of basic and clinical research ranging from the subatomic mechanisms of free radical formation, macromolecular and intracellular radiation-induced alterations, biochemical and physiological mechanisms to the clinical management of radiation casualties (9) . Radioprotective agents, although widely studied in the past four decades and including several thousand agents, have criteria of an optimal radioprotection, including effectiveness, toxicity, availability, specificity and tolerance (10) .
NITROIMIDAZOLES
The first group of compounds which proved to be sufficiently nontoxic for in vivo use and which sensitized hypoxic mammalian cells were the nitroimidazoles (figure 1). These compounds have now received extensive clinical testing throughout the world (11, 12) . Most hypoxic cell radiosensitizers were designed to improve the radiosensitizing activity of misonidazole, primarily by modifying the side chains (13) such as KIN-1800.
Sibel SÜZEN All cells contain varying degrees of non-protein sulfhydryls which act to protect DNA.
As the level of these compounds is reduced to low concentrations either through chemical suppressers such as N-ethylmaleimide or through synthesis blockers such as buthionine-SRsulfoximine, sensitization of the cell occurs (19) . Cellular radiosensitivity is affected by the presence of endogenous intracellular thiols. Oxydation of these thiols by diamide (20, 21) renders the cells more sensitive. Monoethyl and diethyl esters of glutathione had the capacity to provide some protection of normal and buthionine sulfoxime pretreated cells against X-
Ionising radiation induces multiple biological effects through direct interaction with DNA or through formation of free radical species. It has been shown that small doses of hydrogen peroxide can induce protection against subsequent doses of ionizing radiation, which supports the hypothesis that oxidative species or single-strand breaks function as inducers (23, 24) . Ionizing radiation increases oxidative stress followed by glutathione depletion as a result of enchanced detoxification of hydrogen peroxide by glutathion peroxidase (25). Diethyl maleate reacting with glutathione and buthionine sulfoximine inhibiting glutathione synthesis, cause radiosensitization (26).
The original finding that substitution of a halogenated uridine for thimidine in DNA would sensitize to radiation (27) . The degree of sensitization depends on the percentage of DNA which is replaced by the thymidine analogue. The bromenated and iodinated compounds have proved most efficacious.
It has been shown in several systems, including plateau-phase cultured cells and tumours in vivo, that increased survival will occur under certain conditions after radiation exposure (Table 1) (28,29,) . 
OTHER IMPORTANT RADIOPROTECTIVE COMPOUNDS
-Carotene is known to offer some protection against radiation induced toxicity.
Squalene is a 30 carbon chain with 6 double bonds that is structurally similar to -carotene.
Squalene also reduces radiation induced damage by its antioxidant activities and stabilised oxygen radicals (31, 32) . Vitamins C and E have generated a great deal of interest for a wide range of protective effects in biological systems (Figure 4 ) (33). They are known to be synergistic antioxidants in vitro (34) . The role of vitamin C against radiation damage is not only in the initial stages of radical scavenging but also in cellular redox processes mediated by glutathione (35) . 
AMIFOSTINE FOR PROTECTION FROM ANTINEOPLASTIC DRUG TOXICITY
During the initial radiochemical events the presence of sulfhydryl compounds can reduce the permanent lesions in DNA. It is highly likely that endogenous sulfhydryls cause natural radioprotection and that the exogenous sulfhydryls can cause further protection through repair of free radicals in DNA as well as neutralization of free radicals formed in cellular water Figure 6 . Dephosphorylation of WR2127
Normal cells are constantly subjected to both external (UV rays, carsinogens) and internal (metabolic by-products) assaults which cause damage, or genetic lesions, to the DNA molecule. Because the cells structural integrity is dependent on its ability to read and translate DNA, reparing DNA damage is essential to the cells survival. It may be possible to prevent this DNA damage by inhibiting The DNA repair mechanism with a compound such as amifostine.
Considering the mechanism of action, amifostine is a prodrug converted by alkaline phosphatase to the active sulfhydryl compound WR-1065. WR-1065 protects normal cells by scavenging free radicals, donating hydrogen ions to free radicals, depleting oxygen, and binding to active derivatives of antineoplastic agents (40) . The immediate conversion of amifostine to WR-1065, radioprotection starts by scavenging of hydroxyl ion and by chemical DNA repair (by hydrogen donation from its SH function) (39) . Comparison the radioprotective activity of the compounds have free SH groups to compounds have no free SH group such as cystine (which has disulfide bonds), shows that free SH group plays a significant role in protecting the cells from antioxidant-induced cytotoxicity by hydrogen atom transfer reaction to free radicals (18) .
A major mechanism underlying the radioprotective effect of WR2721 is the scavenging highly reactive free radicals induced by ionizing radiation (41) . Since damage inflicted by free radicals is a major event responsible not only for killing mammalian cells by radiation but also for malignant transformation of these cells (42) .
The preclinical evaluation of amifostine confirms selective protection of normal tissues against toxicity due to radiation therapy and alkylating agent chemotherapy (43) . In a broad range of phase II and III clinical studies, amifostine has been shown to substantially reduce anticancer drug-induced toxicities (44) and a novel clinical application of the drug could be in its use to protect against radiation therapy induced genotoxic damage to normal cells (45) . The potential value of such an agent includes reducing treatment related toxicity and the opportunity for radiation dose escalation in the curative treatment of cancer (46) . The selectivity of amifostine for normal tissue is hypothesised to be a result of the decreased vascularity of tumours, decreased activity of alkaline phosphatase in tumour cells, and pH dependence of WR1065 uptake (40) . On the other hand cell type differences in chromatin organisation and DNA-drug associations could play a role in the selective radioprotection as well as the pH value differences between the normal and the tumor cells.
The first evaluation of WR2127 using the iv compound was carried out in Japan (47) .
Then the results suggested that WR1065 which is the dephosphorylated, free thiol active metabolite of WR2721, may enable tissue recover from irridation by promoting the replication of endothelial cells, possibly by mechanisms independent of glutathion (48).
Significant side effects related to amifostine include nausea, vomiting and hypotension which can be ameliorated with appropriate premedication and combination with other drugs such as mitomycin and vinblastine (49) . 
